title: In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
abstract: The in-vitro susceptibilities of a total of 1371 urinary tract pathogens to fosfomycin trometamol were determined. According to the NCCLS breakpoints, Enterobacteriaceae and gram-positive microorganisms were, in general, very sensitive to this antimicrobial. More than 90.0% of the Escherichia coli and Citrobacter spp. and more than 70.0% of the Klebsiella pneumoniae, K. oxytoca, Enterobacter spp., Proteus mirabilis, Staphylococcus aureus, coagulase-negative staphylococci and Enterococcus spp. strains tested were susceptible to fosfomycin trometamol. However, Pseudomonas aeruginosa and Acinetobacter spp. strains were more resistant. In general, recent clinical isolates from urinary tract infections (UTIs) in both community and hospital were also very sensitive (> 80.0%) to fosfomycin, its activity being higher than that of the rest of the antimicrobials commonly used for therapy of uncomplicated UTIs. More than 75.0% of the most frequently isolated pathogens from UTIs, except for P. aeruginosa (31.8%) and Acinetobacter spp. (11.1%), were susceptible to fosfomycin trometamol. The results obtained in this study, together with the infrequency of side effects and its pharmacokinetic properties, indicate that fosfomycin trometamol may be a useful alternative for single-dose therapy of uncomplicated UTIs.
authors.affiliation: Departamento de Microbiología y Parasitología, Hospital Universitario de Salamanca, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: García-Rodríguez
authors.forename: I
authors.initials: I
authors.lastname: Trujillano Martín
authors.forename: F
authors.initials: F
authors.lastname: Baquero
authors.forename: R
authors.initials: R
authors.lastname: Cisterna
authors.forename: M
authors.initials: M
authors.lastname: Gobernado
authors.forename: F
authors.initials: F
authors.lastname: Liñares
authors.forename: F
authors.initials: F
authors.lastname: Martín-Luengo
authors.forename: G
authors.initials: G
authors.lastname: Piédrola
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D005079:Excipients; D005578:Fosfomycin / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D017408:Guidelines as Topic; D006801:Humans; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D013030:Spain; D014325:Tromethamine; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D005079:Excipients; D014325:Tromethamine; D005578:Fosfomycin; D009643:Norfloxacin